AOKI Yoshinori

写真a

Affiliation

Faculty of Medicine College Hospital Mother and child health center of integrated perinatal period

Title

Lecturer

External Link

Related SDGs


Degree 【 display / non-display

  • 博士(医学) ( 2019.3   東京大学 )

Research Areas 【 display / non-display

  • Life Science / Embryonic medicine and pediatrics

 

Papers 【 display / non-display

  • LOX-1 mediates inflammatory activation of microglial cells through the p38-MAPK/NF-κB pathways under hypoxic-ischemic conditions Reviewed

    Aoki Y., Dai H., Furuta F., Akamatsu T., Oshima T., Takahashi N., Goto Y.i., Oka A., Itoh M.

    Cell Communication and Signaling   21 ( 1 )   126   2023.6

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Cell Communication and Signaling  

    Background: Microglial cells play an important role in the immune system in the brain. Activated microglial cells are not only injurious but also neuroprotective. We confirmed marked lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) expression in microglial cells in pathological lesions in the neonatal hypoxic-ischemic encephalopathy (nHIE) model brain. LOX-1 is known to be an activator of cytokines and chemokines through intracellular pathways. Here, we investigated a novel role of LOX-1 and the molecular mechanism of LOX-1 gene transcription microglial cells under hypoxic and ischemic conditions. Methods: We isolated primary rat microglial cells from 3-day-old rat brains and confirmed that the isolated cells showed more than 98% Iba-1 positivity with immunocytochemistry. We treated primary rat microglial cells with oxygen glucose deprivation (OGD) as an in vitro model of nHIE. Then, we evaluated the expression levels of LOX-1, cytokines and chemokines in cells treated with or without siRNA and inhibitors compared with those of cells that did not receive OGD-treatment. To confirm transcription factor binding to the OLR-1 gene promoter under the OGD conditions, we performed a luciferase reporter assay and chromatin immunoprecipitation assay. In addition, we analyzed reactive oxygen species and cell viability. Results: We found that defects in oxygen and nutrition induced LOX-1 expression and led to the production of inflammatory mediators, such as the cytokines IL-1β, IL-6 and TNF-α; the chemokines CCL2, CCL5 and CCL3; and reactive oxygen/nitrogen species. Then, the LOX-1 signal transduction pathway was blocked by inhibitors, LOX-1 siRNA, the p38-MAPK inhibitor SB203580 and the NF-κB inhibitor BAY11-7082 suppressed the production of inflammatory mediators. We found that NF-κB and HIF-1α bind to the promoter region of the OLR-1 gene. Based on the results of the luciferase reporter assay, NF-κB has strong transcriptional activity. Moreover, we demonstrated that LOX-1 in microglial cells was autonomously overexpressed by positive feedback of the intracellular LOX-1 pathway. Conclusion: The hypoxic/ischemic conditions of microglial cells induced LOX-1 expression and activated the immune system. LOX-1 and its related molecules or chemicals may be major therapeutic candidates. [MediaObject not available: see fulltext.].

    DOI: 10.1186/s12964-023-01048-w

    Scopus

    PubMed

  • Short-term outcomes in infants with mild neonatal encephalopathy: a retrospective, observational study Reviewed

    Yoshinori Aoki, Tatsuo Kono, Mikako Enokizono, Kaoru Okazaki

    BMC pediatrics   21 ( 1 )   224   2021.5

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Background: Neonatal encephalopathy due to acute perinatal asphyxia is a major cause of perinatal brain damage. Moderate to severe neonatal encephalopathy is associated with high mortality and morbidity rates. However, the neurodevelopmental outcomes in neonates with mild neonatal encephalopathy are unclear. The primary aim of this single-center observational study was to assess the short-term outcomes in term neonates with mild neonatal encephalopathy due to perinatal asphyxia. A secondary aim was to identify predictors of poor prognosis by identifying the characteristics of these infants according to their short-term outcomes.

    Methods: We retrospectively investigated all infants with perinatal asphyxia at Tokyo Metropolitan Children's Medical Center from January 2014 to December 2019. An abnormal short-term outcome was defined as any one of the following: seizures or abnormal electroencephalography, abnormal brain magnetic resonance imaging obtained within the first 4 weeks of life, and abnormal neurological examination findings at discharge.

    Results: In total, 110 term infants with perinatal asphyxia during the study period were screened and 61 were diagnosed with mild neonatal encephalopathy. Eleven (18 %) of these infants had an abnormal short-term outcome. The median Thompson score at admission was significantly higher in infants with abnormal short-term outcomes than in those with normal short-term outcomes (5 [interquartile range, 4-5.5] vs. 2 [interquartile range, 1-3], p < 0.01). Receiver operating characteristic curve analysis showed that a cutoff value of 4 had high sensitivity and specificity (90.9 and 83.0 %, respectively) for prediction of an abnormal short-term outcome.

    Conclusions: 18 % of infants with mild encephalopathy had an abnormal short-term outcome, such as abnormal brain magnetic resonance imaging findings. The Thompson score at admission may be a useful predictor of an abnormal short-term outcome in infants with mild neonatal encephalopathy.

    DOI: 10.1186/s12887-021-02688-y

    PubMed

  • Effects of Songs Recorded by Parents on the Vital Signs of Preterm Infants: A Randomized Controlled Trial Reviewed

    Aoki Y., Kota Y., Shimada M., Taniguchi T., Yamauchi S., Matsusaka M., Hamasuna K., Watanabe Y., Kodama Y., Moritake H.

    Children   12 ( 2 )   2025.2

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Children  

    Background: Preterm infants often have unstable vital signs and prolonged hospital stays that can hinder parent–infant bonding, especially under COVID-19 restrictions. This study aimed to evaluate whether listening to songs recorded by parents was effective in stabilizing the condition of premature infants. Methods: This randomized controlled study was conducted at the University of Miyazaki Hospital from October 2022 to March 2024 during the COVID-19 pandemic period. The participants were preterm infants born at less than 33 weeks gestation and their parents, all of whom recorded songs. The recorded songs were played daily to the infants in the intervention group, while the control group received usual care. Primary outcomes included vital signs (respiratory rate, pulse oximetry saturation, heart rate) and activity level. Results: Data for 33 preterm infants (intervention, n = 17 [total 749 sessions]; control, n = 16 [total 721 sessions]) were analyzed for changes in vital signs and activity levels. The intervention reduced infants’ respiratory rates (4.1 [95% CI: 2.5–5.6], p < 0.001) and slightly but statistically significantly increased pulse oximetry saturation (0.6 [95% CI: 0.02–1.2], p < 0.044). Conclusions: Recorded parental songs were found to safely stabilize the respiratory status of preterm infants and may serve as an accessible intervention to support parent–infant attachment, particularly in settings with restricted parental visitation.

    DOI: 10.3390/children12020146

    Scopus

    PubMed

  • Safety and efficacy of ripasudil eye drops in preterm infants with retinopathy of prematurity: phase 1/2, open label, single-arm trial Reviewed

    Arima M., Inoue H., Misumi A., Tsukamoto S., Matsushita I., Araki S., Ohta M., Takahashi K., Imazato M., Goto T., Aoki Y., Tagawa K., Hirose M., Fujita Y., Yoshida N., Nakao S., Kondo H., Kusuhara K., Kimura K., Hasegawa S., Ikeda Y., Kodama Y., Moritake H., Ochiai M., Ohga S., Kishimoto J., Todaka K., Ieiri I., Sonoda K.H.

    Japanese Journal of Ophthalmology   68 ( 5 )   490 - 499   2024.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Journal of Ophthalmology  

    Purpose: To assess the safety and efficacy of ripasudil for retinopathy of prematurity (ROP). Study design: Phase 1/2, multicenter, open-label, single-arm, 12-week clinical trial. Methods: Infants born with gestational age (GA) of ≤ 32 weeks or weight of ≤ 1500 g with zone I or II, ≥ stage 1, ROP in both eyes were enrolled. Ripasudil eye drops were administered to patients in both eyes. Phase 1 was a dose-escalation study (once daily for 1 week, then twice daily for 2 weeks); an additional dosing up to 9 weeks was allowed if no safety issues occurred. In phase 2, ripasudil was administered twice daily for up to 12 weeks. Adverse events were assessed. The proportion of patients with type 1 ROP progression, number of days for type 1 ROP progression, and progression to the most advanced ROP stage were estimated. Results: Twenty-four infants were enrolled (phase 1, n = 3; phase 2, n = 21). Nineteen and four patients experienced systemic and ocular adverse events, respectively. Efficacy endpoints were not different between the ripasudil and historical control groups. However, in the GA ≤ 27 weeks subgroup, fewer patients progressed to type 1 ROP in the ripasudil than in the historical control group (P = 0.09). In the GA ≤ 27 weeks subgroups, the 25th percentile for the number of days for type 1 ROP progression was 22 days in the historical control group and 44 days in the ripasudil group. Conclusion: Ripasudil was safe and inhibited/delayed type 1 ROP progression, especially in infants with short GA.

    DOI: 10.1007/s10384-024-01100-3

    Scopus

    PubMed

  • Pulmonary lymphangiectasia in an extremely preterm infant complicated with <i>Ureaplasma</i> pneumonitis

    Sakakibara Kouhei, Yamada Naoshi, Kodama Yuki, Obata Shizuka, Tsuzuki Yasue, Muraoka Junsuke, Aoki Yoshinori, Yamashita Rie, Nakame Kazuhiko, Kaneko Masatoki, Katsuragi Shinji, Tsuzuki Ryo, Sato Yuichiro

    Journal of Japan Society of Perinatal and Neonatal Medicine   59 ( 1 )   116 - 121   2023

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japan Society of Perinatal and Neonatal Medicine  

     Here we report a case of pulmonary lymphangiectasia that caused exacerbation of respiratory status after an infection. A preterm infant born at 23 weeks of gestation without obvious clinical intrauterine infection showed worsening respiratory status and increased c-reactive protein on day 15 of life. Chest X-ray showed consolidation in right upper lobe and whole left lung. Several broad-spectrum antibiotics were administered unsuccessfully. Finally, <i>Ureaplasma urealyticum</i> was detected in sputum culture, and azithromycin was administered. Although the inflammation improved, tension pneumothorax and pulmonary hypertension developed and he died on day 44 of life. At autopsy, there were few findings of lung inflammation, and congenital lymphangiectasia was diagnosed. It seems that exacerbation was triggered by the infection, although there was no remarkable evidence to support causality. There have been few case reports of pulmonary lymphangiectasia in extremely low birth weight infants. This case was considered to be classified as primary, although the respiratory condition at birth was relatively good. There are no clear diagnostic criteria for this disease and no effective treatments. Clinically, neonatologists should keep in mind pulmonary lymphangiectasia if respiratory failure in newborns does not respond to common treatment approach.

    DOI: 10.34456/jjspnm.59.1_116

    CiNii Research

display all >>

Grant-in-Aid for Scientific Research 【 display / non-display

  • 新生児低酸素性虚血性脳症における、LOX-1をターゲットとした新規治療法の開発

    Grant number:24K18861  2024.04 - 2027.03

    独立行政法人日本学術振興会  科学研究費基金  若手研究

      More details

    Authorship:Principal investigator 

  • 低酸素性虚血性脳症におけるミクログリアでのLOX-1の役割解明と新規治療法の開発

    Grant number:20K16875  2020.04 - 2023.03

    独立行政法人日本学術振興会  科学研究費補助金  若手研究

      More details

    Authorship:Principal investigator